<code id='63098A1629'></code><style id='63098A1629'></style>
    • <acronym id='63098A1629'></acronym>
      <center id='63098A1629'><center id='63098A1629'><tfoot id='63098A1629'></tfoot></center><abbr id='63098A1629'><dir id='63098A1629'><tfoot id='63098A1629'></tfoot><noframes id='63098A1629'>

    • <optgroup id='63098A1629'><strike id='63098A1629'><sup id='63098A1629'></sup></strike><code id='63098A1629'></code></optgroup>
        1. <b id='63098A1629'><label id='63098A1629'><select id='63098A1629'><dt id='63098A1629'><span id='63098A1629'></span></dt></select></label></b><u id='63098A1629'></u>
          <i id='63098A1629'><strike id='63098A1629'><tt id='63098A1629'><pre id='63098A1629'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:7
          Mother and child
          Adobe

          The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

          Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

          advertisement

          “This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          VC firm RA Capital starts a new synthetic biology incubator
          VC firm RA Capital starts a new synthetic biology incubator

          AdobeVenturecapitalfirmRACapitalisstartinganewincubator,settingthestageforthefirmtocreatenewstartups

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          VC firm RA Capital starts a new synthetic biology incubator

          AdobeVenturecapitalfirmRACapitalisstartinganewincubator,settingthestageforthefirmtocreatenewstartups